×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LLY – eli lilly and company (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LLY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/4
08:07 pm
lly
Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Neutral
Report
Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/4
06:48 pm
lly
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions [Yahoo! Finance]
Low
Report
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions [Yahoo! Finance]
2/4
05:51 pm
lly
Eil Lilly shares jump on strong GLP-1 sales, as Novo Nordisk tumbles [Yahoo! Finance]
Low
Report
Eil Lilly shares jump on strong GLP-1 sales, as Novo Nordisk tumbles [Yahoo! Finance]
2/4
02:52 pm
lly
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026 [CNBC]
Low
Report
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026 [CNBC]
2/4
02:47 pm
lly
We're raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat [CNBC]
Low
Report
We're raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat [CNBC]
2/4
02:20 pm
lly
Wall Street Lunch: Washington Post Lays Off A Third Of Staff [Seeking Alpha]
Low
Report
Wall Street Lunch: Washington Post Lays Off A Third Of Staff [Seeking Alpha]
2/4
12:43 pm
lly
Eli Lilly (LLY) Stock Trades Up, Here Is Why [Yahoo! Finance]
Low
Report
Eli Lilly (LLY) Stock Trades Up, Here Is Why [Yahoo! Finance]
2/4
12:10 pm
lly
Lilly soars again as fast-selling weight loss drugs top Wall Street projections [Yahoo! Finance]
Low
Report
Lilly soars again as fast-selling weight loss drugs top Wall Street projections [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/4
07:06 am
lly
Form 8-K ELI LILLY & Co For: Feb 04
Low
Report
Form 8-K ELI LILLY & Co For: Feb 04
2/3
04:33 pm
lly
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Yuffa Ilya
Medium
Report
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Yuffa Ilya
2/3
04:32 pm
lly
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Skovronsky Daniel
Medium
Report
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Skovronsky Daniel
2/3
04:31 pm
lly
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Van Naarden Jacob
Medium
Report
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Van Naarden Jacob
2/3
04:29 pm
lly
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Ricks David A
Medium
Report
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Ricks David A
2/3
04:29 pm
lly
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Rau Diogo
Medium
Report
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Rau Diogo
2/3
04:28 pm
lly
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Jonsson Patrik
Medium
Report
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Jonsson Patrik
2/3
04:27 pm
lly
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Hernandez Edgardo
Medium
Report
Form 4 ELI LILLY & Co For: Feb 01 Filed by: Hernandez Edgardo
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Eli Lilly, AbCellera Biologics to co-develop coronavirus therapies [Reuters]
14.2%
3/2 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 5.8%
4/13 Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study [The New York Times] 4.6%
4/2 Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock. 4.2%
3/23 FDA enacts abbreviated approval pathway for insulin biosimilars [Seeking Alpha] 3.2%
4/16 Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available 3.2%
10/28 Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares [Yahoo! Finance News] 2.7%
2/4 Form 4 ELI LILLY & Co For: Feb 01 Filed by: Zulueta Alfonso G 2.7%
12/18 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) 2.7%
3/23 Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic 2.6%
3/2 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 5.8%
4/13 Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study [The New York Times] 4.6%
4/2 Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock. 4.2%
3/23 FDA enacts abbreviated approval pathway for insulin biosimilars [Seeking Alpha] 3.2%
4/16 Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available 3.2%
10/28 Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares [Yahoo! Finance News] 2.7%
2/4 Form 4 ELI LILLY & Co For: Feb 01 Filed by: Zulueta Alfonso G 2.7%
12/18 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) 2.7%
3/23 Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic 2.6%
TOP News Decliners
3/11
Eli Lilly to Participate in Program to Make Insulin Cheaper for Seniors [The Motley Fool]
-10.0%
3/18 Hap Sneddon's Top Picks: March 18, 2020 [Business News Network (BNN) Energy & Resources (Canada)] -7.6%
3/20 Form DEFA14A ELI LILLY & Co -5.8%
7/11 New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache -5.3%
6/9 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions -4.0%
8/14 Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health -4.0%
4/28 Form 8-K ELI LILLY & Co For: Apr 24 -3.5%
2/27 Local Organization NOVA ScriptsCentral Benefits BIG with Eli Lilly release of Bulk Donation Insulin Pens -3.4%
2/21 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease -3.4%
8/5 Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments -3.4%
3/18 Hap Sneddon's Top Picks: March 18, 2020 [Business News Network (BNN) Energy & Resources (Canada)] -7.6%
3/20 Form DEFA14A ELI LILLY & Co -5.8%
7/11 New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache -5.3%
6/9 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions -4.0%
8/14 Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health -4.0%
4/28 Form 8-K ELI LILLY & Co For: Apr 24 -3.5%
2/27 Local Organization NOVA ScriptsCentral Benefits BIG with Eli Lilly release of Bulk Donation Insulin Pens -3.4%
2/21 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease -3.4%
8/5 Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments -3.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: